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ABSTRACT: Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states associated with a variety of pathologies,
including cancer. Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid
(SAHA) is described. Although hydroxamic acids are utilized universally in the development of metalloenzyme inhibitors, they
are considered to be poor pharmacophores with reduced activity in vivo. We developed a prodrug of SAHA by appending a
promoiety, sensitive to thiols, to the hydroxamic acid warhead (termed SAHA-TAP). After incubation of SAHA-TAP with an
HDAC, the thiol of a conserved HDAC cysteine residue becomes covalently tagged with the promoiety, initiating a cascade
reaction that leads to the release of SAHA. Mass spectrometry and enzyme kinetics experiments validate that the cysteine residue
is covalently appended with the TAP promoiety. SAHA-TAP demonstrates cytotoxicity activity against various cancer cell lines.
This strategy represents an original prodrug design with a dual mode of action for HDAC inhibition.
■ INTRODUCTION
Transcription is a tightly regulated biological process that is the
first step in gene expression.1−3 In eukaryotic cells, sequence-
specific DNA binding factors control the flow of genetic
information from DNA to RNA, thereby regulating tran-
scription. In cells, DNA is tightly compacted into chromatin, a
highly organized and dynamic complex between DNA and
proteins. When gene transcription is activated, the DNA is
made accessible to transcription factors via nucleosome
modification.1,2 The local architecture of chromatin, which is
influenced by post-translational modifications of histones, can
regulate gene expression. These modifications include methyl-
ation, phosphorylation, and acetylation of core histones.
Histone acetylation occurs at the ε-amino groups of conserved
lysine residues near the N-termini. Acetylation levels of core
histones are a result of the balance between histone
acetyltransferases (HATs) and histone deacetylases
(HDACs).1−4 Increased levels of histone acetylation are
generally associated with transcriptional activity, whereas
decreased levels of histone acetylation are associated with
repression of transcription. Additionally, acetylation of specific
lysines on histone tails facilitates the recruitment of
bromodomain-containing chromatin remodeling factors.5,6
Furthermore, acetylated lysines have been observed in many
cellular proteins, indicating that HATs and HDACs do not
function solely to modify histones.7
Histone deacetylase inhibitors (HDACi) have been
developed as a class of therapeutic agents intended to target
aberrant epigenetic states associated with a variety of
pathologies, most notably cancer.8 Recent findings have
shown that the relief of oncogenic transcriptional repressors
by HDACi can lead to cell cycle arrest and apoptosis.1−4 This is
because many cancers have evolved such that pro-apoptotic
pathways are transcriptionally repressed via histone deacetyla-
tion. HDACi prevent deacetylation of the lysine residues of the
histone tails, which, in turn, leads to transcriptional activation,
gene expression, and cell death.1,8
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The development of HDACi has been ongoing, and >10
candidates have progressed to clinical trials.3 HDACi can be
subdivided into structural classes including hydroxamic acids,
cyclic peptides, aliphatic acids, and benzamides.9 The HDACi
Vorinostat (suberoylanilide hydroxamic acid, SAHA) received
approval by the United States Food and Drug Administration
(FDA) in 2006 for the treatment of cutaneous T-cell
lymphoma (CTCL).10 Crystallization of SAHA with HDAC8
supported a model involving the linkage of a metal-binding
pharmacophore (MBP) to a capping group designed to form
favorable interactions with amino acid residues at the entrance
to the active site tunnel (Figure 1a).11 Three other HDACi
have been approved by the FDA, including Panobinostat and
Belinostat, both broad-spectrum, hydroxamate-based HDACi
for the treatment of multiple myeloma or relapsed/refractory
peripheral T-cell lymphoma, respectively (Figure 1a).12,13
Romidepsin (FK228), a cyclic peptide HDACi that uses a
thiol group to coordinate the active site metal ion, is approved
for CTCL treatment (Figure 1a).10
SAHA, Romidepsin, and Panobinostat act to inhibit most
isoforms of the metal-dependent HDAC family and are
regarded as broad-spectrum HDAC inhibitors. Despite
promising clinical results for HDACi, these drugs have not
been effective in clinical trials involving solid tumors. In fact,
these FDA-approved drugs have been associated with the onset
of serious side effects, including fatigue, gastrointestinal issues
(diarrhea, nausea, vomiting), and hematologic complications
(thrombocytopenia, anemia, neutropenia).8,10 Both SAHA and
Romidepsin have also been associated with cardiotoxicity.8
Clinical studies in humans determined the major metabolic
pathways of SAHA degradation involve glucoronidation by
UDP-glucoronosyltransferases (UGTs) to generate inactive 1
(Figure 1b). Alternatively, hydrolysis of SAHA to the carboxylic
acid analogue (2) followed by β-oxidation generates the
inactive metabolite 4-anilino-4-oxobutanoic acid (3, Figure
1b).10,14 Clinical studies determined that the mean steady-state
serum exposures of 1 and 2 were 4- and 13-fold higher than
SAHA, respectively. Additionally, the apparent t1/2 of SAHA in
human serum was ∼1.5 h for patients receiving single doses of
400 mg of SAHA.8,10,14 The poor pharmacokinetic (PK)
properties of SAHA are similar for other hydroxamic acid-based
compounds and involve chemical instability and rapid
elimination.8,15 In fact, the FDA has approved SAHA for
CTCL only in patients with persistent or recurrent disease who
have already followed two systemic therapies.8 Similarly, the
FDA has only approved Romidepsin for CTCL treatment in
patients who have received at least one prior systemic therapy,
and Panobinostat is administered only after two prior standard
therapies have failed.16 The onset of these deleterious side
effects is proposed to originate, in part, from the lack of
selectivity of these drugs for a specific HDAC isozyme.8
Chemically modified versions of active drugs have been
developed in an effort to overcome barriers to drug formulation
and delivery. The modified, latent version of the drug, termed
the prodrug, undergoes a transformation in the presence of a
desired chemical or enzymatic stimulus in vivo to generate the
active agent.17,18 The chemical group appended to the active
drug rendering it inactive is termed the promoiety. Only a
handful of reports have investigated HDAC prodrugs, with
most studies focused on developing acyl derivatives of SAHA or
similar hydroxamic acid-based HDACi to enhance cell
permeability and hydrolytic stability.19 As expected, these
prodrugs showed little activity as HDAC inhibitors, and
biochemical assays suggest that the acylated prodrugs are
more cell-permeable than the hydroxamic acid parent drugs. A
similar report investigated a carbamate prodrug concept for
hydroxamate HDACi (including SAHA) to improve drug-like
properties, including cellular permeability.20 However, both of
these strategies rely on hydrolysis in vivo to release the active
drug and do not improve drug−target specificity for selected
disease states or sites of disease.
Initially, we sought to develop new HDAC inhibitor
prodrugs (proinhibitors) that become activated in the presence
of thiols such as glutathione in its reduced form (GSH), which
is frequently more abundant at the site of disease (e.g.,
cancer).21 Previously, Huang and co-workers reported the
development of a long-wavelength fluorescent probe involving
a quinone-methide reaction that can detect physiologically
Figure 1. FDA-approved HDAC inhibitors. (a) The hydroxamic acid and sulfhydryl MBP donor atoms of SAHA, Panobinostat, Belinostat, and
Romidepsin are shown in red. (b) Metabolism of SAHA. Upon systemic circulation, UGT enzymes localized in the liver can convert SAHA to a
SAHA β-D-glucuronide (1), rendering the drug inactive. A different pathway involves initial hydrolysis of SAHA to the corresponding carboxylic acid
(2), followed by oxidation to 3.
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relevant thiols including GSH.22 Although the quinone
promoiety functions as an electrophilic Michael acceptor, it
was determined that other biologically relevant nucleophiles,
including serine and lysine, were unreactive with this
functionality. Our prodrug approach considered the covalent
appendage of this quinone promoiety to the hydroxamate of an
HDACi, since the alkylation of hydroxamates has been shown
to be effective in improving PK properties including hydrolytic
stability, cellular permeability, and glucoronidation.19,23,24
As described below, even in the absence of nucleophilic
thiols, we observed activation of our prodrug (SAHA-TAP);
sequence homology analysis revealed that a single cysteine
(Cys) residue is conserved in all metal-dependent HDAC
isoforms, which we found was reactive with our prodrug
(Supporting Information, Figure S1).25 The crystal structure of
HDAC8 complexed with SAHA reveals that the conserved Cys
(Cys153 for HDAC8) is located in the catalytic active site
pocket ∼5.6 Å away from the hydroxamic acid moiety of SAHA
(Figure 2). Thus, we have concluded that our prodrug is
cleaved by the sulfhydryl moiety of the conserved Cys of
HDAC, leading to drug activation and a dual mode of
inhibition: covalent modification of the conserved Cys leading
to the formation of an inactive, covalently modified enzyme and
release of the competitive inhibitor SAHA.
■ RESULTS AND DISCUSSION
Development of a Unique HDACi Prodrug. SAHA was
chosen as the drug of interest because it is FDA-approved for
the treatment of CTCL and has been well-studied. A prodrug
of SAHA containing a quinone-based, thiol-sensitive promoiety
was designed, termed SAHA-TAP (TAP, thiol activated
prodrug) (Figure 3). To develop SAHA-TAP, the promoiety
was first synthesized using a modified literature procedure.22
The promoiety was appended to SAHA under basic conditions
to generate SAHA-TAP. The activation of SAHA-TAP by
reaction with GSH is summarized in Figure 3a. A control
compound, SAHA-OBn, was synthesized in a similar manner.
This compound contains a benzyl moiety appended to SAHA
via the N-hydroxyl functionality. SAHA-OBn was designed to
have a similar structure as that of SAHA-TAP but to be
unreactive toward nucleophilic thiols.
Assessment of SAHA-TAP Reactivity with GSH. To
evaluate the reactivity of SAHA-TAP and SAHA-OBn with
nucelophilic thiols, analytical HPLC was utilized under
simulated physiological conditions (50 mM HEPES, pH 7.4).
SAHA-TAP was treated with GSH (2 mM, 2 equiv) to confirm
that the prodrug is indeed reactive with thiols. After incubation
of SAHA-TAP with GSH, three distinct peaks were apparent in
the HPLC chromatogram (Figure 3b). Liquid chromatogra-
phy−mass spectrometry (LC-MS) confirms that the identity of
the first peak (tR = 10.5 min) is the quinone-methide side
product, the second peak is SAHA (tR = 10.7 min), and the
third peak is unreacted SAHA-TAP (tR = 14.7 min). Treatment
of SAHA-OBn with GSH under the same conditions resulted in
no change in the HPLC chromatogram, indicative of the
expected lack of reactivity (Figure 3c). Having shown that
SAHA-TAP reacts rapidly with GSH, the aqueous stability of
SAHA-TAP was evaluated under simulated physiological
conditions (50 mM HEPES, pH 7.4). An HPLC chromatogram
was obtained immediately after preparation in aqueous buffer,
and a second trace was collected after incubation at 37 °C for
24 h. SAHA-TAP was determined to be >97% stable to
hydrolysis in the absence of thiols (Figure S2).
HDAC Inhibition by SAHA-TAP. To determine the
efficacy of the SAHA-TAP prodrug strategy, the ability of
SAHA-TAP and SAHA-OBn to inhibit HDAC-1, -2, -3, -6, and
-8 was evaluated using an optimized homogeneous fluo-
rescence-based assay (BPS Bioscience). Surprisingly, even in
the absence of exogenous thiols, SAHA-TAP was an effective
inhibitor of all HDACs tested, with an apparent IC50 value that
is slightly less potent (2- to 50-fold) than that of the parent
inhibitor, SAHA (Table S1). This result was unexpected
because the metal-binding ability of the hydroxamic acid MBP
of SAHA-TAP is blocked by the promoiety, which should
render the drug nearly inactive. Recent studies indicate that the
metal-free form of HDAC8 has a low affinity for SAHA
analogues, further demonstrating the importance of metal
binding for HDAC inhibition.26 To determine if a component
of the biochemical assay resulted in SAHA-TAP activation,
analytical HPLC was utilized. SAHA-TAP was incubated with
either BSA (5 mg/mL) or trypsin (5 mg/mL) at 37 °C for 2 h;
however, SAHA-TAP was found to be >95% stable in the
presence of either of these assay components (data not shown).
Because SAHA-TAP is a larger molecule than SAHA and the
metal-binding hydroxamate group is blocked, it is feasible that
the promoiety may be positioned very close to Cys153 when
bound to HDAC8. This positioning could be ideal for
nucleophilic attack by the sulfhydryl moiety, leading to covalent
modification and SAHA release. We hypothesized that the
Cys153 residue of HDAC8 reacts with bound SAHA-TAP,
resulting in a covalent modification of the protein and
subsequent release of SAHA, a competitive inhibitor (Figure
S3). It is important to note that there are many other Cys
residues in the metal-dependent HDAC isoforms (e.g., 10 Cys
residues in HDAC8), and activation of SAHA-TAP by these
residues may also be responsible, in part, for the release of
SAHA that we observe (vide supra).
Mass Spectrometry Analysis. To investigate whether the
active site Cys153 is covalently modified by the SAHA-TAP
promoiety, mass spectrometry (MS) techniques were utilized.
Digestion of wild-type (WT) HDAC8 with trypsin yields an 18
Figure 2. Protein crystal structure of HDAC8 complexed with SAHA.
The distance between the sulfhydryl moiety of Cys153 and the
nitrogen atom of the MBP of SAHA was determined to be 5.6 Å.
SAHA and Cys153 are shown as sticks in color code (carbon, gray;
nitrogen, blue; oxygen, red; sulfur, yellow), and the Zn2+ ion is shown
as an orange sphere (PDB: 1T69).
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amino acid peptide containing Cys153, which can be used to
monitor the modification via mass spectrometry (Figure 4a). If
a covalent modification occurs at this position after treatment
of WT HDAC8 with SAHA-TAP, then the expected MS ion for
this peptide fragment will be different from the unmodified
parent ion.
HDAC8 (WT, with or without incubation with a 12-fold
excess of SAHA-TAP for 60 min at 37 °C) was digested with
trypsin, and the resulting peptides were analyzed by LC-MS.
The expected parent ion for the WT HDAC8 Cys153 peptide
was consistent with a peak at tR = 84.5 min (Figure 4b).
Similarly, a peak at tR = 88.5 min corresponds to the expected
parent ion for the covalently modified Cys153 HDAC8 peptide
after SAHA-TAP treatment (Figure 4c). To eliminate other
digestion products that could account for this ion, further MS
techniques were applied to verify that these ion peaks
correspond to the peptide sequence of interest.
Tandem mass spectrometry (MS2 or MS/MS) is routinely
used in proteomics to characterize amino acid sequences of
proteins, where peptides undergo further fragmentation to
amino acid aggregates.27 The fragmentation patterns observed
in the MS/MS spectra of tryptic peptides for WT HDAC8 and
SAHA-TAP treated HDAC8 were investigated to obtain
additional insight into the possibility of covalent modification
of Cys153. The expected monoisotopic masses for the y ion
series in both WT HDAC8 and the SAHA-TAP treated sample
are summarized in Table S2. The expected y fragment ions for
both peptides align until Cys153 (y12), where this ion and each
subsequent ion have different masses. Indeed, the MS/MS
fragmentation spectrum for the WT HDAC8 tryptic peptide
(parent ion m/z = 1006.98, [M + 2H]2+) shows many of the
expected y ions (Figure S4). Similarly, the MS/MS
fragmentation spectrum for the SAHA-TAP treated HDAC8
tryptic peptide (parent ion m/z = 1059.53 [M + 2H]2+) shows
many y ions, including the characteristic peak of m/z = 1511.82
(Figure S5). This peak is indicative of a covalent modification
of m/z = 162.1 for the HDAC8 tryptic fragment at Cys153.
These data prove that the covalent modification of Cys153 is
occurring to form an adduct containing the SAHA-TAP
promoiety, as shown in Figure S3.
MS analysis also indicated that Cys102, Cys244, and Cys314
could be modified by the TAP moiety from SAHA-TAP.
Importantly, the peptides containing surface cysteines (Cys275
and Cys352) were not modified with TAP, suggesting that
activation is not nonspecific. Nonetheless, the hypothesized
mechanism of activation involving a covalent modification of
Cys residues in HDAC8, including Cys153, was observed,
which can aid in explaining the inhibition of HDACs by SAHA-
TAP even in the absence of exogenous nucleophilic thiols, as
observed in the in vitro assays.
In Vitro Time Dependence of SAHA-TAP HDAC
Inhibition. With the MS data in hand confirming covalent
modification of Cys residues in HDAC8, we sought to
investigate the kinetics of inhibition of HDAC8 by SAHA-
Figure 3. (a) Activation of SAHA-TAP by GSH. In the presence of GSH, the sulfhydryl moiety can attack the electrophilic quinone moiety.
Subsequent rearrangement releases SAHA along with a quinone-methide adduct. (b) HPLC trace of SAHA (black), SAHA-TAP (blue), and SAHA-
TAP after treatment with GSH (2 mM, 2 equiv) for 2 h at 37 °C (red). Retention times are 10.7 min for SAHA, 14.7 min for SAHA-TAP, and 10.5
min for the quinone-methide GSH adduct generated from the reaction. (c) HPLC trace of SAHA (black), SAHA-OBn (blue), and SAHA-OBn after
incubation in HEPES (50 mM, pH 7.4) for 24 h at 37 °C (red). Retention times are 10.7 min for SAHA and 14.9 min for SAHA-OBn.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00539
J. Med. Chem. 2015, 58, 4812−4821
4815
TAP using the Fluor-de-Lys activity assay (Enzo Life Sciences).
A previous study determined that the catalytic activity and thus
inhibition of HDAC8 is dependent on the identity of the active
site metal ion (e.g., Co2+, Fe2+, Zn2+, and Ni2+).28 To obtain the
most accurate results, apo-HDAC8 (human, recombinant) was
initially prepared before the addition of Zn2+ in a 1:1
stoichiometry. An initial test of HDAC8 inhibition by
preincubation of the enzyme with SAHA-TAP demonstrated
that activity loss occurred within the first 0.5 h (data not
shown). To determine the kinetics for the time-dependent
Figure 4. HDAC8 tryptic fragment MS data. (a) Expected HDAC8 Cys153 peptide upon digestion with trypsin (Cys153 in bold). The expected MS
ion for the WT protein is shown along with the expected ion for the peptide including the covalent addition of the TAP promoiety on Cys153. (b)
The tryptic fragment of WT HDAC8 (tR = 84.5 min) is consistent with the expected [M + 2H]
2+ ion. (c) After treatment of HDAC8 with SAHA-
TAP (12 equiv) and digestion with trypsin, a peak aligning with the expected [M + 2H]2+ ion is observed (tR = 88.5 min).
Figure 5. Time dependence of HDAC8 inhibition. (a) WT HDAC8 (0.5 μM) progress curves at varying concentrations (0−20 μM) of SAHA-TAP.
Dependence of both the (b) initial rate, v0, and (c) kobs on the concentration of SAHA-TAP. (d) C153A HDAC8 (2 μM) progress curves at varying
concentrations (0−20 μM) of SAHA-TAP.
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inhibition by SAHA-TAP, HDAC8 progress curves were
measured through a range of inhibitor concentrations (Figure
5a). For these reactions, the Fluor-de-Lys HDAC8 substrate
(150 μM) and SAHA-TAP (0−20 μM) were added to each
assay prior to initiating the reactions with WT HDAC8 (0.5
μM). Over a time course, aliquots of the reactions were
stopped by dilution into a solution of trichostatin A and trypsin,
and product formation was analyzed from the resulting change
in fluorescence. Analysis of the HDAC8 progress curves in the
presence of increasing concentrations of SAHA-TAP demon-
strates a nonlinear formation of product with respect to time.
Equation 1, which describes the time-dependent decrease in
initial velocity under steady-state turnover conditions,29,30 was
fit to the progress curves
= + − × − −
+
P
v t v v k t
k C
( ) ( ) [1 exp( )]ss 0 obs
obs (1)
where P represents production formation, vs and v0 represent
final and initial velocities, respectively, t is time, C is the initial
fluorescent ratio, and kobs is the rate constant describing the
transition from the initial velocity to the final steady-state
velocity, reflecting the time-dependent enzyme inactivation.
This fit reveals that both the initial velocity and the rate
constant for inactivation, kobs, have a hyperbolic dependence on
the concentration of SAHA-TAP (Figures 5b,c). The initial
velocity decreases with an apparent Ki = 7 ± 4 μM, and the rate
constant for inactivation increases with a K1/2 = 8 ± 2 μM to a
maximal rate constant of 0.0013 s−1 at saturating SAHA-TAP.
This type of inhibition is characteristic of a two-step mechanism
(Scheme 1) in which a rapid reversible step, such as binding of
SAHA-TAP to HDAC8, is followed by a time-dependent step,
consistent with irreversible inactivation.29,30 These data
demonstrate that the prodrug, SAHA-TAP, is capable of
binding to and inhibiting HDAC8. The time-dependent
decrease in activity is consistent with the MS data
demonstrating the formation of a covalent enzyme adduct.
·+ ⇌ ⎯→⎯ −EE I I E I
K kI obs (Scheme 1)
For comparison, progress curves for inhibition of HDAC8
with the competitive inhibitor SAHA and a negative control,
SAHA-OBn, were evaluated. These assays were performed in
the same manner as the SAHA-TAP progress curves, where
substrate and inhibitor were added to the assay prior to the
addition of HDAC8 to initiate the reaction. In contrast to the
data with SAHA-TAP, these progress curves are linear with no
observable curvature for all concentrations of SAHA (Figure
S6a) and SAHA-OBn (Figure S6b). As expected, HDAC8 (0.5
μM) is inhibited >90% by SAHA in the concentration range
tested (2−8 μM), which is in agreement with the 250 nM Ki
reported for Zn2+-HDAC8.28 SAHA-OBn (2−10 μM) does not
inhibit the activity of HDAC8. The lack of inhibition by SAHA-
OBn is consistent with previous IC50 data (Table S1). Taken
together, these data show that SAHA-TAP has a unique mode
of inhibition for HDAC8 when compared to SAHA. This
inhibitor functions both as a competitive inhibitor and as a
time-dependent inactivator, in contrast to the linear, time-
independent inhibition observed for SAHA.
To determine the role of Cys153 in the time-dependent
inhibition of HDAC8, a Cys153Ala (C153A) HDAC8 mutant
was prepared and purified. In vitro assays for the mutant were
conducted under the same conditions used for WT HDAC8.
Progress curves for these assays reveal dose-responsive
inhibition with Ki = 8 ± 4 μM for SAHA-TAP (Figures 5d
and S7). Furthermore, these progress curves are linear for all
concentrations of inhibitor, showing a loss of the time-
dependent inhibition observed with WT HDAC8. This data
suggests that SAHA-TAP, containing the same linker spacer
and capping group as SAHA, can bind HDAC8 in a
noncovalent manner, inhibiting the enzyme (Scheme 1). The
linear progress curves also demonstrate that Cys153 is
important for the time-dependent inactivation, eliminating an
alternate explanation that the time-dependent inhibition is due
to the slow formation of SAHA from SAHA-TAP. Progress
curves with C153A HDAC8 measured with SAHA and SAHA-
OBn data reveal that the HDAC8 mutant remains susceptible
to inhibition by SAHA and not SAHA-OBn (Figure S8).
Collectively, these data indicate both that SAHA-TAP binds
noncovalently to HDAC8 to inhibit the activity and that the
time-dependence mainly reflects the reaction of SAHA-TAP
with Cys153. Although the MS data suggests that SAHA-TAP
can react with other Cys residues in HDAC8, leading to SAHA
release, C153A HDAC8 is not inactivated in a time-dependent
manner, demonstrating the importance of this particular Cys in
the mechanism of inhibition for the WT enzyme. The
combination of the enzyme kinetics and MS data provides
evidence that the inactivation of HDAC8 by SAHA-TAP
involves two steps: noncovalent binding of SAHA-TAP to
HDAC8 followed by covalent modification of Cys153.
Plasma Stability. As mentioned earlier, SAHA suffers from
poor PK properties, including hydrolytic instability with t1/2 ∼
1.5 h. To determine the stability of SAHA-TAP in a biologically
relevant model, human plasma stability studies were conducted
as previously reported.31 After incubating SAHA or SAHA-TAP
in human plasma, aliquots were withdrawn at various time
points (0, 15, 30, 60, and 120 min), quenched with acetonitrile,
filtered, and evaluated via analytical HPLC. The percent parent
compound remaining was determined by integrating the area
under the curve and comparing this number with the initial
sample of parent compound at an incubation time of 0 min.
Approximately 72% of SAHA-TAP remained after 1 h
incubation at 37 °C, whereas only ∼60% of SAHA remained
under identical conditions. Only ∼50% of either parent
compound remained after a 2 h incubation at 37 °C (Figure
6a). After 2 h incubation at 37 °C, the HPLC trace of SAHA-
TAP showed that the major degradation peak (∼23%)
corresponds to SAHA, with ∼52% SAHA-TAP remaining and
∼25% other products. This suggests that hydrolysis of SAHA-
TAP to SAHA is a major component of the degradation
process in human plasma (Figure S9). For comparison, after a 2
h incubation in human plasma under identical conditions, the
HPLC chromatogram for SAHA shows the emergence of a
series of new unidentifiable peaks (∼45%), with ∼55% SAHA
remaining (Figure S9). Even though SAHA-TAP gradually
degrades over this 2 h period, it is relatively slow and results in
the release of the active drug SAHA. Efforts to identify other
product peaks via LC-MS were inconclusive. Overall, this study
indicates that SAHA-TAP has a moderately improved stability
profile than SAHA in human plasma.
Cell Proliferation Studies. With the kinetics of activation
and plasma stability of SAHA-TAP elucidated, we then studied
the effect of SAHA-TAP on the proliferation of a variety of cell
lines. Because SAHA is FDA-approved for CTCL, we selected
HH (CTCL) and Jurkat (T-cell leukemia) cell lines for analysis.
The viability of NIH/3T3 (mouse embryo fibroblast) was also
tested to determine the toxicity of each compound for a
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noncancer cell line. The EC50 values of SAHA, SAHA-TAP, and
SAHA-OBn are shown in Figure 6b for each cell line. The
observed EC50 values of SAHA for HH and for Jurkat cell lines
were 1.03 ± 0.21 μM and 1.66 ± 0.14 μM, respectively,
consistent with previously reported data.32,33 SAHA-TAP is
∼3−4-fold less potent than SAHA, but it is still an active
compound, with calculated EC50 values of 3.38 ± 0.30 μM and
6.05 ± 0.14 μM for HH and Jurkat cells, respectively. This
difference in potency may be attributed to the alkylated Cys
affecting the binding of SAHA to HDAC8; further structural
studies are needed to confirm this hypothesis. Interestingly,
SAHA also is toxic for NIH/3T3 cell lines, with a calculated
EC50 of 4.80 ± 0.99 μM. Other studies also report cytotoxicity
of healthy kidney cells (Vero) after treatment with SAHA
(EC50 = 5.20 ± 0.96 μM).
28 Unfortunately, cell proliferation
studies indicate that SAHA-TAP is also slightly toxic for NIH/
3T3 cells with an apparent EC50 value of 9.37 ± 1.21 μM. As
expected, cell proliferation is unaffected by the addition of
SAHA-OBn for all cells studied.
Intracellular Target Validation.With the cell proliferation
data in hand for both Jurkat and HH cells, we sought to validate
the intracellular target of SAHA-TAP using western blotting
techniques. Broad-spectrum HDACi are known to increase the
steady-state accumulation of tubulin, an endogenous HDAC
substrate and a common marker for intracellular HDAC6
activity.34,35 For these experiments, SAHA was used as a
positive control, since it has been shown to dramatically
increase tubulin acetylation in a variety of cells.33,36 Indeed, we
observed that SAHA-TAP increased tubulin acetylation in both
Jurkat and HH cells without disturbing actin levels (Figure 6c),
suggesting that the antiproliferative mechanism of action for
SAHA-TAP, like SAHA, involves nonspecific HDAC inhibition.
■ CONCLUSIONS
A thiol-sensitive prodrug of the FDA-approved HDACi SAHA
has been developed that displays a time-dependent inhibition of
HDAC8. SAHA-TAP functions as a dual-mode HDAC
inhibitor with both a covalent modification and a noncovalent,
conventional mode of action. SAHA-TAP is susceptible to
nucleophilic attack by Cys residues on the target HDAC,
particularly the conserved Cys153 residue in the catalytic
domain of HDAC8. These Cys residues are covalently modified
with the promoiety, inactivating the enzyme, followed by the
release of the competitive inhibitor SAHA. Proteomic MS
confirms that this modification occurs at Cys153, and the
kinetics of inhibition show unambiguous time-dependent
inhibition of HDAC8 by SAHA-TAP, indicative of a covalent
modification with release of SAHA. The HDAC8 C153A
mutant retains the noncovalent mode of inhibition by SAHA-
TAP (Scheme 1), whereas the time-dependent mode of
inhibition disappears. This result demonstrates the importance
of the active site Cys in the inactivation of HDAC8 by SAHA-
TAP. The stability of SAHA-TAP in human plasma is slightly
improved, with slow conversion to SAHA observed. In contrast,
SAHA is rapidly degraded to several products under identical
conditions, consistent with previous literature studies. Finally,
cellular proliferation studies show a clear dose−response
relationship with SAHA-TAP for two distinct cancer cell
lines, with only moderately inferior EC50 values compared to
SAHA; immunoblotting confirms that the antiproliferative
Figure 6. (a) Plasma stability for SAHA (red circles) and SAHA-TAP (black squares) over time (mean ± SD). (b) Cellular EC50 values (μM)
obtained from the MTS cell proliferation assay. NI, no inhibition at 50 μM. (c) Western blot analysis of tubulin acetylation for Jurkat (lanes 1−5)
and HH (lanes 6−10) cells. Lane 1, control (no treatment); lane 2, SAHA (1.5 μM); lane 3, SAHA (20 μM); lane 4, SAHA-TAP (6 μM); lane 5,
SAHA-TAP (20 μM); lane 6, control (no treatment); lane 7, SAHA (1.5 μM); lane 8, SAHA (20 μM); lane 9, SAHA-TAP (6 μM); lane 10, SAHA-
TAP (20 μM).
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mechanism of action of SAHA-TAP involves HDAC inhibition.
To the best of our knowledge, SAHA-TAP is the first dual-
mode HDAC proinhibitor that exploits the modification of
endogenous, conserved Cys residues, namely, the catalytic site
Cys153 residue in HDAC8, to generate a covalent adduct in
addition to releasing a competitive inhibitor.
■ EXPERIMENTAL SECTION
Enzyme Inhibition Assays. HDAC-1, -2, -3, -6, and -8 activity
was determined in vitro with an optimized homogeneous assay
performed in a 384-well plate. Recombinant, full-length HDAC
protein (BPS Biosciences) was incubated with fluorophore-conjugated
substrate, MAZ1600 and MAZ1675, at [substrate] = Km (MAZ1600;
11 μM for HDAC1, 18 μM for HDAC2, 9 μM for HDAC3, 4 μM for
HDAC6; MAZ1675; 263 μM for HDAC8). Reactions were performed
in assay buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20,
0.05% BSA, pH 7.4, and additional 200 μM TCEP was added for
HDAC6) and followed by fluorogenic release of 7-amino-4-
methylcoumarin from substrate upon deacetylase and trypsin
enzymatic activity. Flourescence measurements were obtained every
5 min using a multilabel plate reader and plate stacker (Envision;
PerkinElmer). Each plate was analyzed by plate repeat, and the first
derivative within the linear range was imported into analytical software
(Spotfire DecisionSite). Replicate experimental data from incubations
with inhibitor were normalized to DMSO controls ([DMSO] < 0.5%).
IC50 values are determined by logistic regression with unconstrained
maximum and minimum values.
Mass Spectrometry Experiments. Preparation. An aliquot of
HDAC8 (1.7 μM) was incubated with SAHA-TAP (12 equiv, 20 μM)
at 37 °C for 1 h. The protein was purified by SDS-PAGE followed by
Coomassie staining prior to analysis.
In Gel Digest. The gel slices of interest were cut to 1 mm cubes
and destained three times by first washing with 100 mM ammonium
bicarbonate (100 μL) for 15 min followed by the addition of ACN
(100 μL) for 15 min. The supernatant was collected, and samples were
dried in a SpeedVac. The samples were then reduced by the addition
of 100 μM ammonium bicarbonate/10 mM DTT (200 μL) and
incubated at 56 °C for 30 min. The liquid was removed, and 100 mM
ammonium bicarbonate/55 mM iodoacetamide (200 μL) was added
to gel pieces and incubated at RT in the dark for 20 min. After the
removal of the supernatant and one wash with 100 mM ammonium
bicarbonate for 15 min, the same volume of ACN was added to
dehydrate the gel pieces. The solution was then removed, and the
samples were dried in a SpeedVac. For digestion, enough solution of
ice-cold trypsin (0.01 μg/mL) in 50 mM ammonium bicarbonate was
added to cover the gel pieces, which were then incubated on ice for 30
min. After complete rehydration, the excess trypsin solution was
removed, replaced with fresh 50 mM ammonium bicarbonate, and
incubated overnight at 37 °C. The peptides were extracted twice by
the addition of 0.2% formic acid and 5% ACN (50 μL) and vortex
mixing at RT for 30 min. The supernatant was removed and saved. A
total of 50 μL of 50% ACN/0.2% formic acid was added to the sample,
which was vortexed again at RT for 30 min. The supernatant was
removed and combined with the supernatant from the first extraction.
The combined extractions were analyzed directly by LC-MS.
LC-MS/MS. Trypsin-digested peptides were analyzed by HPLC
coupled with tandem mass spectrometry (LC-MS/MS) using
nanospray ionization. The nanospray ionization experiments were
performed using a TripleTOF 5600 hybrid mass spectrometer
(SCIEX) interfaced with nanoscale reversed-phase HPLC (Tempo)
using a 10 cm × 100 μm i.d. glass capillary packed with 5 mm C18
Zorbax beads (Agilent Technologies). Peptides were eluted from the
C18 column into the mass spectrometer using a linear gradient (5−
60%) of ACN at a flow rate of 250 μL/min for 1 h. The buffers used to
create the ACN gradient are buffer A (98% H2O, 2% ACN, 0.2%
formic acid, and 0.005% TFA) and buffer B (0.2% formic acid and
0.005% TFA in ACN). MS/MS data were acquired in a data-
dependent manner in which the MS1 data was acquired for 250 ms at
m/z of 400 to1250 Da and the MS/MS data was acquired from m/z of
50 to 2000 Da. Independent data acquisition (IDA) parameters were
MS1-TOF 250 ms followed by 50 MS2 events of 25 ms each. The IDA
criteria were as follows: over 200 counts threshold, charge state +2−4,
with 4 s exclusion. Finally, the collected data were analyzed using
MASCOT (Matrix Sciences).
Protein Expression and Purification. Recombinant human
HDAC8 in a pET-20b-derived plasmid with an added C-terminal
TEV protease cleavage site and His6 tag (termed pHD)
28 was
expressed and purified in Escherichia coli BL21(DE3) according to
Gantt and co-workers,28 with the following modification: elution from
the nickel columns was performed using a linear gradient (10−250
mM imidazole). In the preparation of apo-enzyme, HDAC8 was
dialyzed twice at 4 °C against 4 L of 25 mM MOPS, 1 mM EDTA, 5
mM KCl, 1 mM TCEP, pH 7.5, followed by four times against 2 L of
25 mM MOPS, 5 mM KCl, 1 mM TCEP, pH 7.5. All components
were free of transition metals, and dialysis occurred in plasticware that
had been washed with EDTA and rinsed with Milli-Q ddH2O. Apo-
enzyme was stored at −80 °C in the same metal-free buffer. The
Cys153Ala HDAC8 mutant was constructed in a pHD4 TEV-His
plasmid, using the QuikChange site-directed mutagenesis protocol and
kit, and the mutation was confirmed by the UM DNA sequencing
facility. This construct was expressed and purified in the same manner
as wild-type enzyme.
HDAC8 Time-Course Inhibition Experiments. Recombinant
WT or C153A mutant human HDAC8 was reconstituted for 1 h on
ice at a 1:1 stoichiometry (at 10 μM) with Zn2+ in 1× HDAC assay
buffer (25 mM HEPES, 3 mM KCl, 137 mM NaCl, pH 8.0). The 5
and 50 mM SAHA-TAP, SAHA-OBn, and SAHA stocks were serially
diluted into decreasing concentrations of DMSO to maintain solubility
of the compounds. Reaction mixtures of 1× HDAC assay buffer, 150
μM Fluor-de-Lys peptide substrate (R−H−K(Ac)−K(Ac)−fluoro-
phore) (Enzo Life Sciences), and various concentrations of inhibitors
(SAHA-TAP, SAHA-OBn, or SAHA) were prepared and allowed to
equilibrate at 30 °C. The final DMSO content was <1%. Assays were
initiated by addition of wild-type (0.5 μM) or Cys153Ala mutant (2
μM) HDAC8. At various time points, a reaction aliquot (5 μL) was
diluted into a Fluor-de-Lys quench solution (45 μL) containing trypsin
and trichostatin A (TSA). Assays were read in 96-well plates (Corning
3686) using a PolarStar fluorescent plate reader. The fluorescence
corresponding to product formation (λex = 340 nm, λem = 450 nm)
and remaining substrate (λex = 340 nm, λem = 380 nm) was measured,
and the ratio of product formed/remaining substrate is reported.
Standard curves demonstrate that this fluorescent ratio linearly reflects
product under these conditions.
Cell Proliferation Studies. HH and Jurkat cell lines were obtained
from ATCC (Manassas, VA, USA) and grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY,
USA). The NIH/3T3 cell line was kindly donated by Dr. Richard
Klemke and grown in DMEM medium supplemented with 10% fetal
bovine serum (Gibco, Grand Island, NY, USA) at 37 °C in an
incubator with 5% CO2. The CellTiter 96 aqueous one solution cell
proliferation assay (MTS) kit was purchased from Promega (Madison,
WI, USA). Cell viability was measured using the MTS assay according
to the manufacturer’s protocol. To start the assay, cells were counted
with a hemocytometer, diluted with fresh medium to the proper
concentration, and seeded in 96-well plates (5000 cells/well for NIH/
3T3 and 20 000 cells/well for HH and Jurkat). Jurkat and HH cells
were then directly incubated in media containing the various
concentrations of drugs for 70 h (ranging from 0.5 to 128 μM).
NIH/3T3 cells were first incubated at 37 °C with 5% CO2 for 16 h
prior to the drug treatment for cell attachment. The cells were then
treated with various concentrations of drugs for 70 h. The CellTiter 96
aqueous one solution was added (20 μL per well), and the plate was
incubated at 37 °C for 2 h (NIH 3T3) or 4 h (HH and Jurkat). The
absorbance was recorded at 490 nm using the BioTek Synergy HT
microplate reader. Each concentration of drug treatment was
conducted in triplicate for each trail, with 2−3 trials conducted.
Plasma Stability. The plasma stability of SAHA and SAHA-TAP
was investigated with pooled normal human plasma (Innovative
Research, Novi, MI). In duplicate, plasma (1.0 mL) was preincubated
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for 2 min at 37 °C followed by the addition of 20 μL of a 5.0 mM
stock solution (DMSO). Aliquots (100 μL) were withdrawn at 0, 15,
30, 60, and 120 min and immediately quenched with 100 μL of ACN
to precipitate the proteins. The samples were vortexed thoroughly and
centrifuged for 2 min at 13 000 rpm. The supernatant was collected
and centrifuged through 0.2 μm spin filters (Corning) for 5 min at
8000 rpm. Samples were then frozen until analyzed by HPLC with the
following method: analytical HPLC was performed on a HP Series
1050 system equipped with a Poroshell 120 reverse-phase column
(EC-C18, 4.6 × 100 mm, 2.7 μm). Separation was achieved with a flow
rate of 1 mL min−1 and the following mobile phase: 2.5% ACN + 0.1%
formic acid in H2O (A) and 0.1% formic acid in ACN (B). Starting
with 95% A and 5% B, a linear gradient was run for 15 min to a final
solvent mixture of 5% A and 95% B, which was held for 5 min before
ramping back down to 95% A and 5% B over the course of 2 min, with
constant holding at this level for 4 additional min.
Western Blot Analysis. Log phase growing HH and Jurkat cell
lines were cultured until 70% percent confluent and treated with
specified concentrations of compounds for 4 h prior to harvesting.
Cells were spun at 250g and washed with DPBS buffer (Life
Technologies) before lysis using RIPA buffer (50 mM Tris-HCl (pH
7.5), 150 mM Na2EDTA, 1% Nonidet P-40, 1% sodium deoxycholate,
0.1% sodium dodecyl sulfate) supplemented with complete protease
inhibitor cocktail (Roche) for 30 min on ice. Samples were then spun
at 12 000g before quantification of total protein concentration using a
BCA assay (Thermo). Dilutions were made to normalize total protein
concentration for each gel sample. Diluted samples were then run on a
10% SDS-PAGE gel at 100 V for 2 h before transfer onto Immobilon-P
PVDF Membrane (EMD Millipore) at 100 V for 45 min before
blocking in 5% (v/v) Casein-TBST (Tris-buffered saline Tween-20;
0.05% Tween-20 v/v) at 4 °C. Blots were then incubated with
monoclonal mouse anti-acetylated tubulin (Life Technologies),
polyclonal rabbit anti-tubulin (Sigma), or anti-actin−HRP (Santa
Cruz) in 5% (v/v) BSA-TBST at dilutions according to manufacturer’s
instructions overnight at 4 °C. Blots were then washed by three 5 min
washes in TBST (0.05% v/v); anti-acetylated tubulin and anti-tubulin
antibodies were then incubated with HRP-conjugated anti-mouse
(Santa Cruz) or anti-rabbit (Pierce) antibodies. Detection was
performed using SuperSignal West pico substrate (Pierce) with 10%
(v/v) SuperSignal West femto substrate (Pierce) and imaged on
ChemiDoc XRS+ System with Image Lab Software (Bio-Rad).
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